相似文献
1
RNAi and small interfering RNAs in human disease therapeutic applications.
Trends Biotechnol. 2010 Nov;28(11):570-9. doi: 10.1016/j.tibtech.2010.07.009. Epub 2010 Sep 15.
2
Small interfering RNA-based molecular therapy of cancers.
Chin J Cancer. 2013 Sep;32(9):488-93. doi: 10.5732/cjc.012.10280. Epub 2013 Jan 18.
3
Prospects for the potential of RNA interference in the treatment of autoimmune diseases: Small interfering RNAs in the spotlight.
J Autoimmun. 2020 Nov;114:102529. doi: 10.1016/j.jaut.2020.102529. Epub 2020 Aug 8.
4
Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections.
Curr Mol Pharmacol. 2020;13(3):173-181. doi: 10.2174/1874467212666191023120954.
5
Vector-based delivery of siRNAs: in vitro and in vivo challenges.
Front Biosci. 2008 May 1;13:3488-93. doi: 10.2741/2943.
6
Nanoparticle-based delivery system for application of siRNA in vivo.
Curr Drug Metab. 2010 Feb;11(2):182-96. doi: 10.2174/138920010791110863.
7
Knocking down disease: a progress report on siRNA therapeutics.
Nat Rev Genet. 2015 Sep;16(9):543-52. doi: 10.1038/nrg3978.
8
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Appl Microbiol Biotechnol. 2007 Aug;76(1):9-21. doi: 10.1007/s00253-007-0984-y. Epub 2007 Apr 25.
9
Recent applications of RNAi in mammalian systems.
Curr Pharm Biotechnol. 2004 Aug;5(4):355-60. doi: 10.2174/1389201043376724.
10
Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.
Mol Diagn Ther. 2018 Oct;22(5):551-569. doi: 10.1007/s40291-018-0338-8.
引用本文的文献
1
Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.
Exploration (Beijing). 2024 May 24;5(1):20230165. doi: 10.1002/EXP.20230165. eCollection 2025 Feb.
2
A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS/FTD.
Nat Commun. 2025 Jan 8;16(1):460. doi: 10.1038/s41467-024-55548-5.
3
RNA Interference Unleashed: Current Perspective of Small Interfering RNA (siRNA) Therapeutics in the Treatment of Neuropathic Pain.
ACS Pharmacol Transl Sci. 2024 Sep 23;7(10):2951-2970. doi: 10.1021/acsptsci.4c00329. eCollection 2024 Oct 11.
4
The role of long non-coding RNA in Crohn's disease.
Heliyon. 2024 Jun 6;10(11):e32606. doi: 10.1016/j.heliyon.2024.e32606. eCollection 2024 Jun 15.
5
Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.
Front Microbiol. 2024 Jun 13;15:1393646. doi: 10.3389/fmicb.2024.1393646. eCollection 2024.
6
Nanoliposomes as nonviral vectors in cancer gene therapy.
MedComm (2020). 2024 Jun 25;5(7):e583. doi: 10.1002/mco2.583. eCollection 2024 Jul.
7
RNA Interference Reveals the Impacts of on Imidacloprid Resistance in .
Insects. 2024 Mar 13;15(3):188. doi: 10.3390/insects15030188.
8
Advances in Nucleic Acid Research: Exploring the Potential of Oligonucleotides for Therapeutic Applications and Biological Studies.
Int J Mol Sci. 2023 Dec 21;25(1):146. doi: 10.3390/ijms25010146.
9
A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS/FTD.
bioRxiv. 2023 Dec 12:2023.12.12.571328. doi: 10.1101/2023.12.12.571328.
10
Reduction of UreB and CagA expression level by siRNA construct in Helicobacter pylori strain SS1.
BMC Microbiol. 2023 Dec 19;23(1):401. doi: 10.1186/s12866-023-03143-x.
本文引用的文献
1
Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.
Mol Biosyst. 2010 May;6(5):862-70. doi: 10.1039/b918869j. Epub 2010 Feb 9.
2
Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus.
Antiviral Res. 2010 Sep;87(3):307-17. doi: 10.1016/j.antiviral.2010.06.004. Epub 2010 Jun 16.
3
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
Sci Transl Med. 2010 Jun 16;2(36):36ra43. doi: 10.1126/scitranslmed.3000931.
4
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs.
Retrovirology. 2010 Jun 8;7:52. doi: 10.1186/1742-4690-7-52.
5
Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors.
Nucleic Acids Res. 2010 Oct;38(19):6652-63. doi: 10.1093/nar/gkq460. Epub 2010 Jun 4.
6
Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter.
Hum Gene Ther. 2010 Nov;21(11):1555-67. doi: 10.1089/hum.2010.050. Epub 2010 Oct 6.
7
Posttranscriptional regulation of microRNA biogenesis in animals.
Mol Cell. 2010 May 14;38(3):323-32. doi: 10.1016/j.molcel.2010.03.013.
8
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.
Nature. 2010 May 13;465(7295):227-30. doi: 10.1038/nature08999.
9
The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro.
Int J Nanomedicine. 2010 Mar 9;5:129-36. doi: 10.2147/ijn.s8503.
10
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.
Zotero 插件